Intravitreal Lucentis 0.5mg
Pre-clinicalUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Visual Disorder Due to Age-related Macula Degeneration
Conditions
Visual Disorder Due to Age-related Macula Degeneration
Trial Timeline
Dec 1, 2013 → Dec 1, 2015
NCT ID
NCT02158624About Intravitreal Lucentis 0.5mg
Intravitreal Lucentis 0.5mg is a pre-clinical stage product being developed by Novartis for Visual Disorder Due to Age-related Macula Degeneration. The current trial status is unknown. This product is registered under clinical trial identifier NCT02158624. Target conditions include Visual Disorder Due to Age-related Macula Degeneration.
What happened to similar drugs?
3 of 9 similar drugs in Visual Disorder Due to Age-related Macula Degeneration were approved
Approved (3) Terminated (3) Active (5)
Hype Score Breakdown
Clinical
3
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02158624 | Pre-clinical | UNKNOWN |
Competing Products
13 competing products in Visual Disorder Due to Age-related Macula Degeneration
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 40 |
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 40 |
| Blink® Tears eye drops + Investigational lipid eye drops | Johnson & Johnson | Phase 1 | 29 |
| Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Johnson & Johnson | Phase 2 | 35 |
| Ranibizumab | Novartis | Phase 3 | 40 |
| Ranibizumab + Aflibercept | Novartis | Approved | 35 |
| Ranibizumab | Novartis | Approved | 43 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 40 |
| Sham injections + Ranibizumab 0.5 mg | Novartis | Phase 3 | 32 |
| Ranibizumab + Dexamethasone implant and sham injections | Novartis | Phase 3 | 40 |
| Ranibizumab + Aflibercept | Novartis | Approved | 35 |
| ZK200775 + ZK200775 + Sodium Chloride | Bayer | Phase 1 | 26 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 27 |